MedTrace Logo

Alcohol Biosensor Monitoring for Alcoholic Liver Disease

NCT03533660 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 33

Last updated 2022-11-07

Study results available
· View outcomes & findings →

Summary

Successful treatment of alcohol associated liver disease (AALD) depends primarily on abstinence from alcohol. The investigators propose a randomized clinical trial of alcohol biosensor monitoring for patients with alcohol associated liver disease to determine if monitoring with feedback on alcohol use patterns reduces alcohol consumption and improves outcomes.

Conditions

  • Alcohol Use, Unspecified

Interventions

BEHAVIORAL

Feedback

Participant will receive a brief feedback on alcohol use data downloaded from the ABM and information about treatment resources

BEHAVIORAL

Enhanced Usual Care

Participant will receive information on self reported alcohol use and information about remaining abstinent and about treatment resources

Sponsors & Collaborators

  • National Institute on Alcohol Abuse and Alcoholism (NIAAA)

    collaborator NIH

  • University of Pittsburgh

    lead OTHER

Principal Investigators

  • Andrea DiMartini, MD · University of Pittsburgh

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-09-13
Primary Completion
2021-02-28
Completion
2021-06-28

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03533660 on ClinicalTrials.gov